BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3226Biotechnology
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$3.91M+147.3% YoY
Operating profit-$34.75M-90.9% YoY
Net profit-$29.94M-92.7% YoY
Diluted EPS-$0.54-82.6% YoY
Free cash flow-$26.82M-55.7% YoY
Operating cash flow-$26.05M

Revenue, last 8 quarters

$933.0KDec '24$1.4MMar '25$1.6MJun '25$1.6MSep '25$1.9MDec '25$3.2MMar '26$3.4MJun '26$3.9MSep '26

Net profit, last 8 quarters

$-12.1MDec '24$-15.0MMar '25$-18.1MJun '25$-15.5MSep '25$-15.1MDec '25$-18.3MMar '26$-24.1MJun '26$-29.9MSep '26

Diluted EPS by quarter

-0.35Dec '24-0.43Mar '25-0.34Jun '25-0.30Sep '25-0.29Dec '25-0.38Mar '26-0.44Jun '26-0.54Sep '26

Free cash flow by quarter

$-15.0MDec '24$-19.4MMar '25$-17.7MJun '25$-17.2MSep '25$-19.4MDec '25$-26.1MMar '26$-21.8MJun '26$-26.8MSep '26

Annual revenue

$0.0FY22$0.0FY23$1.5MFY24$6.5MFY25

Profitability & balance sheet

Operating margin-837.5%
Net margin-706.8%
Return on equity-53.6%
Return on assets-21.6%
Return on invested capital-59.4%
Current ratio14.22
Liabilities / assets13.8%
Cash & investments$492.93M
Total debt$9.38M
Net cash (debt)$483.55M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $3.91M $3.38M $3.23M $6.50M $1.87M
Total Operating Revenue $3.91M $3.38M $3.23M $6.50M $1.87M
Operating Expense $38.65M $32.28M $25.93M $81.18M $19.25M
Selling and Admin Expenses $5.88M $6.40M $5.34M $12.60M $2.51M
-General & Admin Expense $5.88M $6.40M $5.34M $12.60M $2.51M
Research & Development $32.13M $25.28M $20.04M $67.45M $16.49M
Depreciation & Amortization & Depletion $647,000.00 $599,000.00 $556,000.00 $1.13M $242,000.00
-Depreciation & Amortization $647,000.00 $599,000.00 $556,000.00 $1.13M $242,000.00
Operating Profit -$34.75M -$28.90M -$22.71M -$74.68M -$17.38M
Net Non-Operating Interest Income (Expense) $4.82M $4.77M $4.38M $11.01M $2.25M
Non-Operating Interest Income $4.82M $4.77M $4.38M $11.01M $2.25M
Other Income (Expense) -$14,000.00 -$10,000.00 -$3,000.00 -$56,000.00 -$11,000.00
Other Non-Operating Income (Expenses) -$14,000.00 -$10,000.00 -$3,000.00 -$56,000.00 -$11,000.00
Pretax Profit -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Net Profit -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Profit from Continuing Operations -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Net Income to Parent Company -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Net Income to Common Stockholders -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Basic EPS -$0.54 -$0.44 -$0.38 -$1.21 -$0.29
Diluted EPS -$0.54 -$0.44 -$0.38 -$1.21 -$0.29

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $532.48M $557.60M $576.80M $264.89M $264.89M
Total Current Assets $499.89M $524.54M $543.94M $230.31M $230.31M
Cash and Cash Equivalents & Short-Term Investments $492.93M $517.32M $538.48M $226.79M $226.79M
-Cash and Cash Equivalents $68.32M $82.49M $371.63M $37.78M $37.78M
-Short Term Investments $424.61M $434.83M $166.85M $189.00M $189.00M
Other Current Assets $6.96M $7.22M $5.46M $3.52M $3.52M
Total Non-Current Assets $32.60M $33.06M $32.86M $34.58M $34.58M
Net PPE $27.11M $28.20M $28.11M $27.25M $27.25M
-Gross PPE $35.12M $35.27M $34.31M $32.79M $32.79M
-Accumulated Depreciation -$8.02M -$7.08M -$6.20M -$5.55M -$5.55M
Other Non-Current Assets $5.49M $4.86M $4.75M $7.33M $7.33M
Total Liabilities $73.61M $72.76M $70.69M $411.03M $411.03M
Total Current Liabilities $35.16M $32.13M $27.91M $31.24M $31.24M
Payables $1.44M $2.53M $1.23M $1.74M $1.74M
-Accounts Payable $1.44M $2.53M $1.23M $1.74M $1.74M
Current Accrued Expenses $12.52M $8.19M $5.05M $4.96M $4.96M
Short-Term Debt and Capital Lease Obligation $1.46M $1.48M $1.43M $1.32M $1.32M
-Current Capital Lease Obligation $1.46M $1.48M $1.43M $1.32M $1.32M
Current Deferred Liabilities $15.23M $17.34M $18.96M $18.66M $18.66M
Total Non-Current Liabilities $38.45M $40.63M $42.78M $379.80M $379.80M
Long Term Debt and Capital Lease Obligation $9.38M $9.76M $10.15M $10.23M $10.23M
-Long Term Capital Lease Obligation $9.38M $9.76M $10.15M $10.23M $10.23M
Non-Current Deferred Liabilities $29.07M $30.87M $32.63M $36.16M $36.16M
Convertible preferred securities $0.00 $0.00 $0.00 $333.41M $333.41M
Total Equity $458.87M $484.84M $506.11M -$146.15M -$146.15M
Stockholders' Equity $458.87M $484.84M $506.11M -$146.15M -$146.15M
Capital Stock $5,000.00 $5,000.00 $5,000.00 $0.00 $0.00
-Common Stock $5,000.00 $5,000.00 $5,000.00 $0.00 $0.00
Additional Paid-In Capital $689.77M $684.61M $681.23M $10.37M $10.37M
Retained Earnings -$228.97M -$199.03M -$174.89M -$156.56M -$156.56M
Gains/Losses Not Affecting Retained Earnings -$1.93M -$745,000.00 -$241,000.00 $42,000.00 $42,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$26.05M -$20.59M -$24.24M -$64.13M -$15.24M
Net cash flow from continuing operations -$26.05M -$20.59M -$24.24M -$64.13M -$15.24M
Net Income from Continuing Operations -$29.94M -$24.14M -$18.33M -$63.73M -$15.14M
Depreciation & Depletion & Amortization $942,000.00 $879,000.00 $652,000.00 $2.33M $695,000.00
Change in Working Capital $1.41M $489,000.00 -$9.06M -$3.23M -$1.19M
-Change in Receivables -$278,000.00 -$144,000.00 -$1.11M $1.03M $804,000.00
-Change in Prepaid Assets $540,000.00 -$1.62M -$828,000.00 -$872,000.00 -$1.13M
-Change in Payables and Accrued Expense $5.59M $5.50M -$1.89M $2.16M $903,000.00
-Change in Other Current Assets -$142,000.00 $488,000.00 -$1.69M $1.35M $417,000.00
-Change in Other Current Liabilities -$404,000.00 -$350,000.00 -$327,000.00 -$1.40M -$317,000.00
-Change In Other Working Capital -$3.91M -$3.38M -$3.23M -$5.50M -$1.87M
Net cash flow from investing $10.17M -$268.71M $20.54M $65.96M -$126.46M
Net Cash Flow from Continuing Investing Activities $10.17M -$268.71M $20.54M $65.96M -$126.46M
Net PPE Purchase and Sale -$772,000.00 -$1.26M -$1.85M -$9.58M -$4.15M
Net Investment Purchase and Sale $10.95M -$267.45M $22.40M $75.55M -$122.30M
Financing Cash Flow $1.71M $156,000.00 $337.55M -$1.21M -$772,000.00
Net Cash Flow from Continuing Financing Activities $1.71M $156,000.00 $337.55M -$1.21M -$772,000.00
Net Common Stock Issuance $0.00 $0.00 $339.78M – –
Proceeds from Stock Option Exercised $1.71M $156,000.00 $30,000.00 $336,000.00 $258,000.00
Net Other Financing Charges $0.00 $0.00 -$2.26M -$1.55M -$1.03M
Ending Cash Balance $69.47M $83.64M $372.78M $38.93M $38.93M
Net Change in Cash -$14.17M -$289.14M $333.85M $625,000.00 -$142.47M
Beginning Cash Balance $83.64M $372.78M $38.93M $38.31M $181.40M
Free Cash Flow -$26.82M -$21.85M -$26.10M -$73.71M -$19.40M
Net Preferred Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on AKTS.

Sign in to join the discussion.

Scroll to Top